Every year, more people die of adverse drug effects than in transportation accidents. Every day, thousands of pharmaceutical preparations are administered to patients who will not experience any relief at all, or much worse, which will suffer from toxicity and thus, eventually develop severe adverse effects.
Guidance to the physician is offered by pharmacogenomics, which is a key factor in the concept of personalized medicine. Pharmacogenomics uses genetic information to evaluate the patient's abilities to metabolize a drug (pharmacokinetics) or to bind a drug (drug targets). In the first case, testing usually consists of analysis of single nucleotide polymorphisms, or SNPs, of drug-metabolizing enzymes, whereas in the second case, the target of a drug is analyzed to check whether the drug efficiently binds to it.
Interestingly, the possibilities that pharmacogenomics provide go beyond drug and dosage recommendations. Other applications may be the evaluation of drug-drug interactions, gathering explanations in case of lacking response, or even patient management. Indeed, blood concentrations of a drug well below the therapeutic window can originate from the patient's metabolism itself, but also from a bad compliance. Pharmacogenomics' testing allows the physician to discriminate in such cases.
This also illustrates that pharmacogenomics and other medical fields such as therapeutic drug monitoring should be considered to be complementary; together, they can offer valuable insights and have the power to break the dogma of "one disease, one drug, and one dosage". Please see examples of our Pharmacogenomics Products:
Pharmacogenomics' testing may be performed on either a blood or a saliva sample and only requires one test in a lifetime, as genetic information does not change. In the effort to provide the best possible guidance to the physician and the patient, Laboratoires Réunis have developed the PHARMAgen product line.